New hepatitis c drug combo shows promise in early trial
NCT ID NCT01010646
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a new form of interferon (IFN alfa-2b XL) combined with ribavirin works better and causes fewer side effects than the standard treatment for chronic hepatitis C (genotypes 1 or 4). 84 adults who had not been treated before or had not responded to previous therapy took part. The main goal was to measure how much the virus level dropped after 4 and 12 weeks of treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS C are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpital de la Croix Rousse
Lyon, 69004, France